Oxandrolone in Healthy Adults: A Relative Bioavailability Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03218631 |
Recruitment Status :
Completed
First Posted : July 14, 2017
Last Update Posted : May 3, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Bioavailability | Drug: Oxandrin | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 6 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: |
|
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Pharmacokinetics of a Medium Chain Triglyceride Oil Oxandrolone Solution vs. Tablets in Healthy Adults: A Relative Bioavailability Study |
Actual Study Start Date : | July 10, 2017 |
Actual Primary Completion Date : | November 30, 2017 |
Actual Study Completion Date : | November 30, 2017 |

Arm | Intervention/treatment |
---|---|
Oxandrin
Administration of a single dose of approximately 0.1 mg/kg of a medium chain triglyceride (MCT) oil Oxandrin (oxandrolone) solution vs. 01.mg/kg tablets in a small cohort of healthy adults. Participants will be dosed at two time points one week apart.
|
Drug: Oxandrin
The primary outcome for this study will be measurements of the pharmacokinetics of a single dose of oxandrolone 0.1 mg/kg both in tablet form and in the MCT oil preparation. Blood samples for pharmacokinetics will be drawn at 9 timepoints. Safety will be assessed by recording adverse events and assessment of hepatic function at baseline and one week following oxandrolone dosing. Other Name: Oxandrolone |
- Peak Plasma Concentration (Cmax) curve [ Time Frame: Measurement of Peak Plasma Concentration (Cmax) at 15 min, 30 min, 1, 2, 3, 4, 8, 24, 48 hours on Days 1 and 8 ]The primary outcome for this study will be the pharmacokinetics of a single dose of oxandrolone 0.1 mg/kg both in tablet form and in the MCT oil preparation as measured by peak plasma concentration (Cmax) curve
- Area under the plasma concentration versus time curve (AUC) [ Time Frame: Measurements at 15 min, 30 min, 1, 2, 3, 4, 8, 24, 48 hours on Days 1 and 8 ]The primary outcome for this study will be the pharmacokinetics of a single dose of oxandrolone 0.1 mg/kg both in tablet form and in the MCT oil preparation as measured by the area under the plasma concentration versus time curve (AUC).
- Safety will be assessed by recording adverse events and assessment of hepatic function at baseline and one week following oxandrolone dosing. [ Time Frame: Liver function will be assessed by measuring serum transaminase levels at baseline and 1 week after each oxandrolone dose in the study participants, and any adverse events throughout the study period and up to 1 week after final dosing will be recorded. ]The risks associated with the 2 doses of oxandrolone given during the course of this study are minimal. Known adverse effects of anabolic steroids, including hepatic dysfunction and virilization, are typically associated with longer-term use (months of daily dosing) and are very unlikely to occur in this study.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 35 Years (Adult) |
Sexes Eligible for Study: | Male |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | Only male subjects will be included to avoid the possibility of a pregnant female inadvertently receiving the study drug and to eliminate any cofounders related to gender. Oxandrolone is contraindicated in pregnancy. Subjects will be enrolled without regard to race and ethnicity. |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Male
- Age 18 to 35 years (inclusive) at the time of screening
- Body mass index [BMI, body weight (kg)/height (m)2] below 30 kg/m2
- Medically healthy
Exclusion Criteria:
- Known allergy to anabolic steroids
- Use of any prescription medication currently or within 14 days prior to dosing
- Use of tobacco or nicotine containing products (including smoking cessation products), within 6 months prior to dosing
- Any chronic medical condition
- Seated blood pressure <90/40 mmHg or >140/90 mmHg at screening
- Heart rate <40 or >99 at screening
- Subjects who have taken any investigational drug within 30 days prior to first dose in the current study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03218631
United States, Utah | |
Primary Children's Hospital | |
Salt Lake City, Utah, United States, 84113 |
Principal Investigator: | Phillip T. Burch, MD | University of Utah |
Responsible Party: | Phillip Burch, MD, University of Utah |
ClinicalTrials.gov Identifier: | NCT03218631 |
Other Study ID Numbers: |
99086 |
First Posted: | July 14, 2017 Key Record Dates |
Last Update Posted: | May 3, 2018 |
Last Verified: | May 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Individual Patient data will only be shared with the research team |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
oxandrolone, cardiac |
Oxandrolone Androgens Hormones |
Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Anabolic Agents |